These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 34261463)

  • 1. Real-world effectiveness of primary screening with high-risk human papillomavirus testing in the cervical cancer screening programme in China: a nationwide, population-based study.
    Zhao Y; Bao H; Ma L; Song B; Di J; Wang L; Gao Y; Ren W; Wang S; Wang HJ; Wu J
    BMC Med; 2021 Jul; 19(1):164. PubMed ID: 34261463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age-specific effectiveness of primary human papillomavirus screening versus cytology in a cervical cancer screening program: a nationwide cross-sectional study.
    Bao H; Ma L; Zhao Y; Song B; Di J; Wang L; Gao Y; Ren W; Wang S; Wu J; Wang HJ
    Cancer Commun (Lond); 2022 Mar; 42(3):191-204. PubMed ID: 35142100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in China: A Multicenter, Open-label, Randomized Clinical Trial.
    Zhang J; Zhao Y; Dai Y; Dang L; Ma L; Yang C; Li Y; Kong L; Wei L; Zhang S; Liu J; Xi M; Chen L; Duan X; Xiao Q; Abulizi G; Zhang G; Hong Y; Gao X; Zhou Q; Xie X; Li L; Niyazi M; Zhang Z; Tuo J; Ding Y; Si M; Chen F; Song L; Qiao Y; Lang J
    JAMA Oncol; 2021 Feb; 7(2):263-270. PubMed ID: 33377903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Real-world research on cervical cancer screening program and effect evaluation for Chinese population].
    Zhao YQ; Dai Y; Dang L; Kong LH; Zhang Y; Feng RM; Qiao YL; Lang JH
    Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):764-771. PubMed ID: 30392341
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of Different HPV-based Strategies and Cytology in Routine Cervical Cancer Screening Programme in China: A Population-based Study.
    Wang S; Li L; Yang J; Han N; Bao H; Wang HJ
    Cancer Prev Res (Phila); 2022 Jan; 15(1):45-54. PubMed ID: 34556493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study.
    Smith MA; Sherrah M; Sultana F; Castle PE; Arbyn M; Gertig D; Caruana M; Wrede CD; Saville M; Canfell K
    BMJ; 2022 Mar; 376():e068582. PubMed ID: 35354610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic accuracy of high-risk HPV DNA genotyping for primary cervical cancer screening and triage of HPV-positive women, compared to cytology: preliminary results of the PIPAVIR study.
    Chatzistamatiou K; Moysiadis T; Angelis E; Kaufmann A; Skenderi A; Jansen-Duerr P; Lekka I; Kilintzis V; Angelidou S; Katsiki E; Hagemann I; Tsertanidou A; Koch I; Boecher O; Soutschek E; Maglaveras N; Agorastos T
    Arch Gynecol Obstet; 2017 May; 295(5):1247-1257. PubMed ID: 28337594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 3-year interval is too short for re-screening women testing negative for human papillomavirus: a population-based cohort study.
    Zorzi M; Frayle H; Rizzi M; Fedato C; Rugge M; Penon MG; Bertazzo A; Callegaro S; Campagnolo M; Ortu F; Del Mistro A;
    BJOG; 2017 Sep; 124(10):1585-1593. PubMed ID: 28120382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HPV screening performance indicators in women who previously tested HPV-negative: The second round of Vallecamonica screening programme, Northern Italy.
    Pasquale L; Rossi PG; Carozzi F; Domenighini S; Ruggeri C; Cecconami L; Morana C; Chiaramonte M; Chiudinelli D; Piccolomini M; Marchione R; Confortini M
    J Med Screen; 2020 Dec; 27(4):207-214. PubMed ID: 32102618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Study on the value assessment of various screening programs regarding cervical cancer screening strategy in the rural areas of China].
    Li LY; Qiao ZQ; Zhang MF; Yang JP; Bao YP; An YT; Lei J; Xiong NH; Yu XH; Zhang X; Pan QJ; Qiao YL
    Zhonghua Liu Xing Bing Xue Za Zhi; 2007 Oct; 28(10):964-7. PubMed ID: 18399140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Organized primary human papillomavirus-based cervical screening: A randomized healthcare policy trial.
    Elfström KM; Eklund C; Lamin H; Öhman D; Hortlund M; Elfgren K; Sundström K; Dillner J
    PLoS Med; 2021 Aug; 18(8):e1003748. PubMed ID: 34424907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmatic human papillomavirus testing in cervical cancer prevention in the Jujuy Demonstration Project in Argentina: a population-based, before-and-after retrospective cohort study.
    Arrossi S; Paolino M; Laudi R; Gago J; Campanera A; Marín O; Falcón C; Serra V; Herrero R; Thouyaret L
    Lancet Glob Health; 2019 Jun; 7(6):e772-e783. PubMed ID: 31097279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized Implementation of a Primary Human Papillomavirus Testing-based Cervical Cancer Screening Protocol for Women 34 to 69 Years in Norway.
    Nygård M; Engesæter B; Castle PE; Berland JM; Eide ML; Iversen OE; Jonassen CM; Christiansen IK; Vintermyr OK; Tropé A
    Cancer Epidemiol Biomarkers Prev; 2022 Sep; 31(9):1812-1822. PubMed ID: 35793700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotyping for Human Papillomavirus (HPV) 16/18/52/58 Has a Higher Performance than HPV16/18 Genotyping in Triaging Women with Positive High-risk HPV Test in Northern Thailand.
    Khunamornpong S; Settakorn J; Sukpan K; Suprasert P; Srisomboon J; Intaraphet S; Siriaunkgul S
    PLoS One; 2016; 11(6):e0158184. PubMed ID: 27336913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison of screening performance between primary high-risk HPV screening and high-risk HPV screening plus liquid-based cytology cotesting in diagnosis of cervical precancerous or cancerous lesions].
    Zhao XL; Remila R; Hu SY; Zhang L; Xu XQ; Chen F; Pan QJ; Zhang X; Zhao FH
    Zhonghua Yu Fang Yi Xue Za Zhi; 2018 May; 52(5):469-474. PubMed ID: 29747337
    [No Abstract]   [Full Text] [Related]  

  • 16. The effectiveness of human papillomavirus load, reflected by cycle threshold values, for the triage of HPV-positive self-samples in cervical cancer screening.
    Song F; Du H; Wang C; Huang X; Qu X; Wei L; Belinson JL; Wu R;
    J Med Screen; 2021 Sep; 28(3):318-324. PubMed ID: 32869705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cervical human papilloma virus (HPV) DNA primary screening test: Results of a population-based screening programme in central Italy.
    Passamonti B; Gustinucci D; Giorgi Rossi P; Cesarini E; Bulletti S; Carlani A; Martinelli N; Broccolini M; D'Angelo V; D'Amico MR; Di Dato E; Galeazzi P; Malaspina M; Spita N; Tintori B; Giaimo MD
    J Med Screen; 2017 Sep; 24(3):153-162. PubMed ID: 27614992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
    Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
    Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effectiveness of HPV16 and HPV18 genotyping and cytology with different thresholds for the triage of human papillomavirus-based screening on self-collected samples.
    Song F; Du H; Wang C; Huang X; Wu R;
    PLoS One; 2020; 15(6):e0234518. PubMed ID: 32525936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human papillomavirus testing in young women: clinical outcomes of human papillomavirus triage in a UK cervical screening program.
    McKenna M; McMenamin MM
    Cancer Cytopathol; 2014 Sep; 122(9):702-10. PubMed ID: 24888573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.